Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6712393rdf:typepubmed:Citationlld:pubmed
pubmed-article:6712393lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:6712393lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:6712393lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:6712393lifeskim:mentionsumls-concept:C0001824lld:lifeskim
pubmed-article:6712393lifeskim:mentionsumls-concept:C0007541lld:lifeskim
pubmed-article:6712393lifeskim:mentionsumls-concept:C0040341lld:lifeskim
pubmed-article:6712393lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:6712393lifeskim:mentionsumls-concept:C0549178lld:lifeskim
pubmed-article:6712393lifeskim:mentionsumls-concept:C1880496lld:lifeskim
pubmed-article:6712393lifeskim:mentionsumls-concept:C0443239lld:lifeskim
pubmed-article:6712393pubmed:issue5lld:pubmed
pubmed-article:6712393pubmed:dateCreated1984-5-23lld:pubmed
pubmed-article:6712393pubmed:abstractTextA combination of tobramycin sulfate and cefamandole nafate was used as initial empiric therapy for the treatment of 71 evaluable febrile (temperature greater than 38.5 degrees C) episodes in 64 (neutrophils, less than 1,000/microL) adult patients with cancer and granulocytopenia. Carbenicillin sodium or ticarcillin disodium was substituted for cefamandole in patients with Pseudomonas infections and in patients in whom the initial regimen was unsuccessful. Twenty-nine episodes were randomized to receive tobramycin by continuous infusion, while 42 were randomized to receive tobramycin by interrupted infusion. Twenty-seven (79%) of the 34 documented infections responded to the initial empiric antibiotic combination, ten (83%) of 12 being given continuous infusion and 17 (77%) of 22 being given interrupted infusion of tobramycin. Nephrotoxic reaction occurred in 7% of patients treated with continuous infusion and 15% treated with interrupted infusion, mostly patients older than 60 years. Tobramycin, by either continuous or interrupted infusion, plus cefamandole is safe and efficacious empiric therapy for infections in patients with cancer and granulocytopenia.lld:pubmed
pubmed-article:6712393pubmed:languageenglld:pubmed
pubmed-article:6712393pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6712393pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6712393pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6712393pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6712393pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6712393pubmed:statusMEDLINElld:pubmed
pubmed-article:6712393pubmed:monthMaylld:pubmed
pubmed-article:6712393pubmed:issn0003-9926lld:pubmed
pubmed-article:6712393pubmed:authorpubmed-author:MoranLLlld:pubmed
pubmed-article:6712393pubmed:authorpubmed-author:DeBoerGGlld:pubmed
pubmed-article:6712393pubmed:authorpubmed-author:DuncanIIlld:pubmed
pubmed-article:6712393pubmed:authorpubmed-author:TuffnellP GPGlld:pubmed
pubmed-article:6712393pubmed:authorpubmed-author:FeldRRlld:pubmed
pubmed-article:6712393pubmed:authorpubmed-author:RachlisAAlld:pubmed
pubmed-article:6712393pubmed:authorpubmed-author:PinfoldPPlld:pubmed
pubmed-article:6712393pubmed:issnTypePrintlld:pubmed
pubmed-article:6712393pubmed:volume144lld:pubmed
pubmed-article:6712393pubmed:ownerNLMlld:pubmed
pubmed-article:6712393pubmed:authorsCompleteYlld:pubmed
pubmed-article:6712393pubmed:pagination1005-10lld:pubmed
pubmed-article:6712393pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:meshHeadingpubmed-meshheading:6712393-...lld:pubmed
pubmed-article:6712393pubmed:year1984lld:pubmed
pubmed-article:6712393pubmed:articleTitleEmpiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole.lld:pubmed
pubmed-article:6712393pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6712393pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:6712393pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:6712393pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:6712393pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6712393lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6712393lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6712393lld:pubmed